FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313237408> ?p ?o ?g. }

• W4313237408 endingPage "562" @default.
• W4313237408 startingPage "553" @default.
• W4313237408 abstract "Tirabrutinib is a Bruton's tyrosine kinase inhibitor for treating B-cell malignancies. We report the final results of a Phase I study of tirabrutinib in 17 Japanese patients with B-cell malignancies. Patients were administered tirabrutinib at a dose of 160 mg, 320 mg, or 480 mg once daily, or 300 mg twice daily (N = 3, 3, 4, and 7, respectively). Three patients continued tirabrutinib until study completion (November 30, 2020). Adverse events (AEs) occurred in all 17 patients, with Grade 3-4 AEs in 8 (47.1%), serious AEs in 7 (41.2%), drug-related AEs in 16 (94.1%), and Grade 3-4 drug-related AEs in 6 (35.3%). Drug-related AEs reported in 3 or more patients were rash, vomiting, neutropenia, arthralgia, and malaise. One additional serious AE (benign neoplasm of the lung, unrelated to tirabrutinib) occurred after the previous data cutoff (January 4, 2018). Tirabrutinib administration and response assessment were continued for over 4 years in 4 patients. The overall response rate was 76.5% (13/17 patients). The median (range) time to response and duration of response were 0.9 (0.9-5.9) months and 2.59 (0.08-5.45) years, respectively. These findings demonstrate the long-term safety and efficacy of tirabrutinib in Japanese patients with B-cell malignancies.Clinical trial registration: JapicCTI-142682 ( http://www.clinicaltrials.jp/ )." @default.
• W4313237408 created "2023-01-06" @default.
• W4313237408 creator A5002395792 @default.
• W4313237408 creator A5010120453 @default.
• W4313237408 creator A5013112899 @default.
• W4313237408 creator A5018968800 @default.
• W4313237408 creator A5029450431 @default.
• W4313237408 creator A5031782171 @default.
• W4313237408 creator A5036000764 @default.
• W4313237408 creator A5055192416 @default.
• W4313237408 creator A5056523228 @default.
• W4313237408 creator A5059052214 @default.
• W4313237408 creator A5069130284 @default.
• W4313237408 creator A5079614010 @default.
• W4313237408 creator A5090320088 @default.
• W4313237408 date "2022-12-28" @default.
• W4313237408 modified "2023-09-25" @default.
• W4313237408 title "Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies" @default.
• W4313237408 cites W1829587101 @default.
• W4313237408 cites W1912693401 @default.
• W4313237408 cites W1999128869 @default.
• W4313237408 cites W2012594643 @default.
• W4313237408 cites W2037983836 @default.
• W4313237408 cites W2044066127 @default.
• W4313237408 cites W2071549499 @default.
• W4313237408 cites W2103820395 @default.
• W4313237408 cites W2142099365 @default.
• W4313237408 cites W2154066874 @default.
• W4313237408 cites W2237058775 @default.
• W4313237408 cites W2605172177 @default.
• W4313237408 cites W2787916641 @default.
• W4313237408 cites W2915082572 @default.
• W4313237408 cites W2920747290 @default.
• W4313237408 cites W2922286357 @default.
• W4313237408 cites W2943412515 @default.
• W4313237408 cites W2945468305 @default.
• W4313237408 cites W2976280418 @default.
• W4313237408 cites W2990327685 @default.
• W4313237408 cites W2995536039 @default.
• W4313237408 cites W3010967763 @default.
• W4313237408 cites W3012874730 @default.
• W4313237408 cites W3025701905 @default.
• W4313237408 cites W3029266545 @default.
• W4313237408 cites W3031555133 @default.
• W4313237408 cites W3037142274 @default.
• W4313237408 cites W3042060819 @default.
• W4313237408 cites W3046825703 @default.
• W4313237408 cites W3137578141 @default.
• W4313237408 cites W3139157067 @default.
• W4313237408 cites W3143400277 @default.
• W4313237408 cites W3163036868 @default.
• W4313237408 doi "https://doi.org/10.1007/s12185-022-03514-6" @default.
• W4313237408 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36576659" @default.
• W4313237408 hasPublicationYear "2022" @default.
• W4313237408 type Work @default.
• W4313237408 citedByCount "1" @default.
• W4313237408 countsByYear W43132374082023 @default.
• W4313237408 crossrefType "journal-article" @default.
• W4313237408 hasAuthorship W4313237408A5002395792 @default.
• W4313237408 hasAuthorship W4313237408A5010120453 @default.
• W4313237408 hasAuthorship W4313237408A5013112899 @default.
• W4313237408 hasAuthorship W4313237408A5018968800 @default.
• W4313237408 hasAuthorship W4313237408A5029450431 @default.
• W4313237408 hasAuthorship W4313237408A5031782171 @default.
• W4313237408 hasAuthorship W4313237408A5036000764 @default.
• W4313237408 hasAuthorship W4313237408A5055192416 @default.
• W4313237408 hasAuthorship W4313237408A5056523228 @default.
• W4313237408 hasAuthorship W4313237408A5059052214 @default.
• W4313237408 hasAuthorship W4313237408A5069130284 @default.
• W4313237408 hasAuthorship W4313237408A5079614010 @default.
• W4313237408 hasAuthorship W4313237408A5090320088 @default.
• W4313237408 hasBestOaLocation W43132374081 @default.
• W4313237408 hasConcept C121332964 @default.
• W4313237408 hasConcept C126322002 @default.
• W4313237408 hasConcept C141071460 @default.
• W4313237408 hasConcept C142424586 @default.
• W4313237408 hasConcept C197934379 @default.
• W4313237408 hasConcept C2776694085 @default.
• W4313237408 hasConcept C2777063308 @default.
• W4313237408 hasConcept C2778570526 @default.
• W4313237408 hasConcept C2778715236 @default.
• W4313237408 hasConcept C2780580376 @default.
• W4313237408 hasConcept C2780852908 @default.
• W4313237408 hasConcept C2780873365 @default.
• W4313237408 hasConcept C71924100 @default.
• W4313237408 hasConcept C87355193 @default.
• W4313237408 hasConcept C90924648 @default.
• W4313237408 hasConceptScore W4313237408C121332964 @default.
• W4313237408 hasConceptScore W4313237408C126322002 @default.
• W4313237408 hasConceptScore W4313237408C141071460 @default.
• W4313237408 hasConceptScore W4313237408C142424586 @default.
• W4313237408 hasConceptScore W4313237408C197934379 @default.
• W4313237408 hasConceptScore W4313237408C2776694085 @default.
• W4313237408 hasConceptScore W4313237408C2777063308 @default.
• W4313237408 hasConceptScore W4313237408C2778570526 @default.
• W4313237408 hasConceptScore W4313237408C2778715236 @default.
• W4313237408 hasConceptScore W4313237408C2780580376 @default.
• W4313237408 hasConceptScore W4313237408C2780852908 @default.

• next